---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-013559"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2022-08-01T23:59:59+00:00"
generated_at: "2026-06-24T06:34:27.649171+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA places clinical hold on Beam's BEAM-201 IND for T-ALL/T-LL

## Summary
- FDA clinical hold on BEAM-201 IND for relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma.
- Beam informed via FDA email on July 29, 2022; IND submitted end of June.
- BEAM-201 is an anti-CD7, multiplex-edited allogeneic CAR-T candidate.
- FDA to provide official clinical hold letter within 30 days; Beam plans updates after discussions.

## SEC filing metadata
- accession: 0000950170-22-013559
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2022-08-01T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017022013559/0000950170-22-013559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017022013559/beam-20220801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-013559
- JSON: https://secwatch.observer/filing/0000950170-22-013559.json
- Plain text: https://secwatch.observer/filing/0000950170-22-013559.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.